奥乐妥珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目標 | CD37 |
| 臨床資料 | |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1372645-37-8 |
| ChemSpider |
|
| UNII | |
| 化学信息 | |
| 化学式 | C4660H7136N1246O1452S30 |
| 摩尔质量 | 104,809.42 g·mol−1 |
奥乐妥珠单抗（INN：otlertuzumab；开发代号：TRU‐016）是一种靶向CD37[1]的人源化单克隆抗体，设计用于治疗癌症。[2]
该药物由Emergent BioSolutions开发，已进入淋巴瘤和慢性淋巴细胞白血病的临床试验。[3]
参考资料
[编辑]- ^ Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S. Anti-CD37 targeted immunotherapy of B-Cell malignancies. Biotechnology Letters. December 2018, 40 (11–12): 1459–1466. PMID 30293139. S2CID 52925605. doi:10.1007/s10529-018-2612-6.
- ^ Otlertuzumab (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. [2024-03-19]. （原始内容存档 (PDF)于2013-12-13）.
- ^ Otlertuzumab. ClinicalTrails.gov. U.S. National Library of Medicine.